Citations

Clear

9383 citation(s) found for "Thomas, PS".

Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early‐ Onset Alzheimer’s Disease Study (LEADS) Cohort
Wonderlin, Ryan J., Hammers, Dustin B. , Garcia, Alex Pena, Eloyan, Ani , Taurone, Alexander, Thangarajah, Maryanne, Gao, Sujuan , Kirby, Kala, Aisen, Paul , Griffin, Percy , Iaccarino, Leo, Kramer, Joel H. , Soleimani‐Meigooni, David N. , Rumbaugh, Malia, Touroutoglou, Alexandra , Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan C., Rogalskı, Emily , Salloway, Stephen , Sha, Sharon, Dickerson, Brad C., Apostolova, Liana G. , Polsinelli, Angelina J. , Hammers, Dustin B , Beckett, Laurel , Wang, Sophia , Logan, Paige E. , Dage, Jeffrey L. , Foroud, Tatiana , Koeppe, Robert A. , Kukull, Walter A. , Joie, Renaud La , Mundada, Nidhi S. , Murray, Melissa E. , Nudelman, Kelly , Toga, Arthur W. , Vemuri, Prashanthi , Atri, Alireza , Day, Gregory S. , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S , Wolk, David A. , Womack, Kyle , Carrillo, María C. , Rabinovici, Gil D.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S24 | Pages: No page available

10.1002/alz.083140 Get It

AbstractBackgroundWe examined neuropsychiatric symptoms (NPS) and psychotropic medication use at the midway point of data collection of the Longitudinal Early‐onset Alzheimer’s Disease Study (LEADS). We compared amyloid‐positive early‐onset Alzheimer’s disease (EOAD) participants and amyloid‐negative early‐onset non‐Alzheimer’s disease [EOnonAD]) participants across NPS domains and psychotropic medication categories.Method282 participants enrolled in LEADS were compared across diagnostic groups – amyloid‐positive EOAD (n = 212) and amyloid‐negative EOnonAD (n = 70). All participants were between ages 40 and 64 at baseline. NPS were measured with the Neuropsychiatric Inventory – Questionnaire (NPI‐Q) and Geriatric Depression Scale – Short Form (GDS‐SF). Medications were categorized into psychotropic category (e.g., antidepressants, antipsychotics, benzodiazepines). Groups were compared on NPI‐Q using binary logistic regression adjusting for sex and disease severity, on GDS‐SF using linear regression adjusting for sex and disease severity, and on psychotropic medication use using Chi square or Fisher’s exact test.ResultDemographic data are presented in Table 1. Average total NPI‐Q score was higher in EOnonAD than EOAD (p = .002, ŋp 2 = .03). Regardless of diagnostic group, informants endorsed Affective behaviors most frequently (76.2%). EOAD informants endorsed fewer Distress‐Tension behaviors (p = .02, OR = .498) and Impulse Control behaviors (p = .01, OR = .438). EOAD informants also endorsed apathy (p < .001, OR = .316), irritability (p = .02, OR = .498), and disinhibition (p = .04, OR = .476) at lower frequency than EOnonAD. GDS‐SF showed that the EOnonAD participants self‐reported more symptoms of depression than the EOAD group (p = .002, ŋp 2 = .03). (Table 2A). A minority of participants, regardless of diagnostic group, reported psychotropic medication use (35%). There was higher use in EOnonAD (38%) than EOAD (24%) (p = .03, Cohen W = .14) (Table 2B).ConclusionNPS burden and psychotropic medication use were higher in EOnonAD than EOAD participants, despite EOnonAD being less severely impaired. LEADS continues to collect data. Future studies will examine etiologies that may be larger drivers of NPS than AD neuropathology, mediators (e.g., race, ethnicity) in the association between NPS and diagnostic group classication, compare NPS in EOAD vs. LOAD, and examine longitudinal changes in neuropsychiatric profiles.
Effects of hearing intervention on cognitive decline: Results of the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) randomized trial
Lin, Frank R. , Albert, Marilyn S. , Burgard, Sheila , Gmelin, Theresa , Gravens‐Mueller, Lisa, Huang, Alison , Mosley, Thomas H., Reed, Nicholas S. , Windham, B. Gwen , Pike, James Russell , Arnold, Michelle L. , Chisolm, Theresa Hnath , Couper, David , Deal, Jennifer A. , Goman, Adele M. , Glynn, Nancy W. , Hayden, Kathleen M. , Knopman, David S. , MITCHELL, CHRISTINE M. , Pankow, James S. , Sanchez, Victoria A , Schrack, Jennifer A. , Coresh, Josef

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S24 | Pages: No page available

10.1002/alz.083084 Get It

AbstractBackgroundHearing loss is associated with greater cognitive decline and incident dementia. Whether hearing intervention could reduce cognitive decline in older adults with hearing loss is unknown.MethodThe ACHIEVE study is a randomized trial (NCT03243422) of 70‐84 year‐old adults with untreated hearing loss and free from substantial cognitive impairment that took place at four U.S. sites. Participants were recruited from two study populations: 1) a group of adults participating in a longstanding observational study of cardiovascular health (Atherosclerosis Risk in Communities [ARIC] study), and 2) a group of healthy de novo community volunteers. Participants were randomised (1:1) to hearing intervention (HI; audiological counseling and provision of hearing aids) or a successful aging health education control intervention (SA; sessions with a health educator on chronic disease prevention). The primary intention‐to‐treat endpoint was 3‐year change in a global cognition standardized factor score from a comprehensive neurocognitive battery.Result977 participants (238 ARIC, 739 de novo) underwent randomisation; 490 were assigned to HI and 487 to SA control. Participants from ARIC were older, had more risk factors for cognitive decline, and had lower baseline cognitive scores than the de novo group. In the primary analysis combining the ARIC and de novo groups, 3‐year cognitive change (in S.D. units) was not significantly different between HI and SA control (HI: ‐0·200 [95% CI: ‐0·256,‐0·144]; SA: ‐0·202 [‐0·258,‐0·145]; Difference 0·002 [‐0·077,0·081],p = 0·96). However, prespecified analyses demonstrated significant differences in the effect of HI on cognitive change between the ARIC and de novo group (p interaction = 0·010). In the ARIC group, HI was associated with a 48% reduction in 3‐year cognitive change compared to SA control (HI: ‐0·211 [‐0·349,‐0·073]; SA: ‐0·402 [‐0·536, ‐0·267]; Difference 0·191 [0·022,0·360,p = 0·027]). In the de novo group, cognitive change was not significantly different between HI and SA control (HI: ‐0·213 [‐0·277,‐0·148]; SA: ‐0·151 [‐0·215,‐0·087]; Difference ‐0·061 [‐0·151,0·028,p = 0·18]). The rate of cognitive change among control participants was observed to be 2.7‐fold faster in the ARIC versus de novo group.ConclusionHearing intervention may have a significant effect on reducing cognitive change over 3 years in populations of older adults at increased risk for cognitive decline.
Cognitive Clusters of Early‐onset non‐Alzheimer’s disease
Kim, Hee Jin , Lane, Kathleen A. , Gao, Sujuan , Hammers, Dustin B. , Aisen, Paul , Eloyan, Ani , Iaccarino, Leo, Kramer, Joel H. , Rumbaugh, Malia, Soleimani‐Meigooni, David N. , Taurone, Alexander, Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan C., Rogalskı, Emily , Salloway, Stephen , Sha, Sharon, Dickerson, Brad C., Apostolova, Liana G. , Hammers, Dustin B , Logan, Paige E. , Dage, Jeffrey L. , Foroud, Tatiana , Grinberg, Lea T. , Jack, Clifford R. , Koeppe, Robert A. , Kukull, Walter A. , Joie, Renaud La , Mundada, Nidhi S. , Murray, Melissa E. , Nudelman, Kelly , Toga, Arthur W. , Vemuri, Prashanthi , Atri, Alireza , Day, Gregory S. , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S , Wolk, David A. , Carrillo, María C. , Rabinovici, Gil D.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S24 | Pages: No page available

10.1002/alz.083061 Get It

AbstractBackgroundApproximately 10‐25% of amnestic early‐onset dementia are negative for amyloid (Early‐onset non‐Alzheimer’s Disease, EOnonAD). EOnonAD is a heterogenous group with various etiologies. In order to better understand the traits of EOnonAD, we clustered amnestic EOnonAD individuals according to cognitive patterns.MethodCognitive data of 62 EOnonAD individuals from the Longitudinal Early‐onset AD study (LEADS) were Z‐normalized to 91 intact individuals after adjusting for age, sex, and education. This led to domain‐averaged composite Z‐scores for memory, language, speed/attention, visuospatial, and executive function. Cluster analysis using the Ward method on the residuals for the five composites was performed. We used Scree plot using the pseudo T‐squared to determine the optimal number of clusters. We compared demographics, imaging biomarkers (amyloid and tau PET SUVR, hippocampal volume), plasma (pTau231, Aß40, Aß42, glial fibrillary acidic protein, and neurofilament light chain (NfL)), and cerebrospinal fluid (CSF) biomarkers (Aß42/40, NfL, Neurogranin, Visinin‐like protein, YKL‐40, and Synaptosome Associated Protein 25) across the clusters after adjusting for age, sex, and education. We compared gray matter density of each EOnonAD cluster to controls (n = 84) using voxel‐wise multiple linear regressions in SPM12, adjusting for age, sex, education, and intracranial volume.ResultScree plot using the pseudo‐T‐squared suggested three clusters. Cluster 1 (38/62, 61.3%) was characterized by having the mildest cognitive impairment in all domains. Cluster 2 (19/62, 30.6%) was characterized by more severe memory and language impairment. Cluster 3 (5/62, 8.1%) was characterized by more severe impairment in speed/attention, visuospatial, and executive function (Table 1). Cluster 3 showed significantly higher NfL for both plasma (Cluster 1 vs 3, p<0.001; Cluster 2 vs 3, p < 0.004) and CSF (Cluster 1 vs 3, p = 0.001). Other biomarkers did not show significant difference (Table 1). Only Cluster 3 showed significant atrophy in the bilateral fronto‐parietal areas at p<0.01, uncorrected (Figure 1).ConclusionWe identified heterogeneity in cognitive patterns among amnestic EOnonAD individuals. Cluster 1 had mildest cognitive impairment; Cluster 2 had predominant impairment in memory and language; and Cluster 3 had predominant impairment in speed/attention, visuospatial, and executive function, with significant fronto‐parietal atrophy and high NfL indicating active neurodegeneration.
Six Year Effects of Hearing Treatment on Cognitive Decline and Dementia: Design and Statistical Considerations of the Aging and Cognitive Health Evaluation in Elders – Brain Health Follow‐Up Study
Huang, Alison , Burgard, Sheila , Gravens‐Mueller, Lisa, Mitchelle, Christine, Mosley, Thomas H., Reed, Nicholas S. , Lin, Frank R. , Pike, James Russell , Arnold, Michelle L. , Chisolm, Theresa Hnath , Couper, David , Deal, Jennifer A. , Goman, Adele M. , Hayden, Kathleen M. , Jack, Clifford R. , Pankow, James S. , Sanchez, Victoria A , Schrack, Jennifer A. , Coresh, Josef

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S23 | Pages: No page available

10.1002/alz.077301 Get It

AbstractBackgroundHearing loss is associated with cognitive decline and dementia. The ongoing ACHIEVE Study was the first randomized trial to test the effects of hearing treatment on three‐year cognitive change. The ACHIEVE – Brain Health Follow‐Up Study will extend follow‐up to six years post‐randomization to determine the long‐term and potentially nonlinear effects of hearing treatment vs. health education control with delayed treatment on dementia and cognitive decline.MethodsParticipants will be recruited from the 977 participants enrolled in the ACHIEVE Study. After Year 3, hearing intervention participants will continue to receive hearing care and the control group will be offered the hearing intervention. Co‐primary study outcomes will be cognitive decline and a composite of incident mild cognitive impairment (MCI)/probable dementia. Secondary outcomes include domain‐specific cognitive decline, brain structural changes on magnetic resonance imaging (MRI), and other functional outcomes (e.g., physical activity, social isolation). Power analyses for the co‐primary outcomes assumed an annual attrition rate of 10% and an immediate, lagged, or cumulative treatment effect.ResultsWhen comparing multi‐year cognitive decline (Table 1), in the scenario of a constant treatment effect that assumes a strong and immediate treatment effect, the benefit of extended follow‐up is not greater power, but additional information on the long‐term effects of hearing intervention. In a scenario of a lagged treatment effect, a two‐year lag in the treatment effect causes the Year 3 assessment to be severely underpowered (28%) but provides sufficient power (80%) at Year 6 despite attrition. In a scenario of a cumulative treatment effect that increases with time, analyses are similarly underpowered at Year 3 (65%) but not at Year 6 (82%). The same pattern is evident when estimating the power at Year 3 (57%) and Year 6 (80%) to detect incident MCI/probable dementia in a Cox regression model that assumes a protective hazard ratio of 0.70 (Figure 1).ConclusionAcross all non‐constant scenarios of potential treatment effect, six years of follow‐up increases precision and provides valuable information to better delineate long‐term cognitive trajectories. The ACHIEVE ‐ Brain Health Follow‐Up Study will be completed in 2025.
Social engagement, amyloid burden, and dementia: the Atherosclerosis Risk in Communities (ARIC)‐PET study
Groechel, Renée C. , Liu, Albert C. , Palta, Priya, Sharrett, Richey, Wong, Dean F. , Liu, Chelsea , Knopman, David S. , Koton, Silvia , Kucharska‐Newton, Anna , Lutsey, Pamela L. , Mosley, Thomas H. , Walker, Keenan A. , Gottesman, Rebecca F.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S22 | Pages: No page available

10.1002/alz.073671 Get It

AbstractBackgroundAlthough amyloid deposition in the brain is often associated with subsequent dementia risk, not everyone with brain amyloid will develop dementia. This discrepancy illustrates the potential importance that risk factors and lived experiences may have in modifying this association. Compared to participants with low social engagement (SE) in mid‐life, we hypothesized that participants with high mid‐life SE will show a weaker association between amyloid burden and incident dementia.MethodWe included data from 310 non‐demented participants of the Atherosclerosis Risk in Communities (ARIC)‐PET study. Social support and isolation were assessed via interviewer‐administered questionnaires (Visit 2; 1990 – 1992). Based upon categorization of both factors, participants were classified as having high, intermediate, or low mid‐life SE (Table 1). Brain amyloid was evaluated with florbetapir PET (Visit 5; 2011‐2014). Elevated amyloid burden was defined as standardized uptake value ratio (SUVR) >1.2 in the global cortex. Incident dementia cases were identified from visit 5 through 2019 through ongoing surveillance utilizing in‐person neurocognitive testing, informant interviews, and hospitalization codes. Relative contributions of mid‐life SE and elevated florbetapir SUVR to incident dementia, independently and with multiplicative interaction terms, were evaluated with Cox regression models, adjusted for demographics, APOEε4 and vascular risk factorsResultAmong 310 participants, 48 developed dementia (median follow‐up: 4.7 years). Mid‐life SE and elevated SUVR each independently predicted dementia risk but did not interact on a multiplicative scale. Participants with high or intermediate mid‐life SE, relative to low mid‐life SE, were less likely to develop dementia (Table 2). Although the interaction between mid‐life SE and elevated SUVR was not significant, stratified models suggested a stronger association between amyloid burden and dementia in participants with high mid‐life SE (Table 3).ConclusionGreater mid‐life SE was associated with lower odds of developing dementia, independent of elevated SUVR. Although protective, there was no strong evidence for effect modification of mid‐life SE on the association between amyloid and dementia risk. Future longitudinal studies evaluating the potential influence of social factors measured throughout the life course are needed to inform our understanding as to what factors may preserve cognition in the presence of elevated brain pathology.
Associations between neuropsychiatric symptoms, pathology in neuropathological cohorts of Alzheimer’s disease, Alzheimer’s disease with Lewy bodies and Dementia with Lewy bodies
Shakir, Neha , Belden, Christine M. , Mehta, Shyamal H. , Shill, Holly A. , Driver‐Dunckley, Erika, Beach, Thomas G. , Tremblay, Cécilia , Zhang, Nan , Adler, Charles H. , Driver‐Dunckley, Erika , Serrano, Geidy E. , Atri, Alireza , Choudhury, Parichita

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S18 | Pages: No page available

10.1002/alz.079470 Get It

AbstractBackgroundNeuropsychiatric symptoms (NPS) are frequent in Alzheimer’s Disease dementia (ADD) but a higher NPS burden is found in dementia with Lewy bodies (DLB). Lewy body (LB) pathology frequently co‐occurs with AD pathology and may not meet neuropathological criteria for DLB (ADLB). Previous studies have shown that both ADLB and DLB cases have faster cognitive and/or functional decline compared to AD. However, the differences in NPS severity over disease course and survival in these pathologic subgroups is not well understood.MethodCases from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) with a final neuropathologic diagnosis of DLB (±AD co‐pathology; n = 65), ADLB (n = 89), AD (without LB) (n = 140), and controls (no neuropathological diagnosis) (n = 82) were included. Total NPI‐Q (scores ranging from 0‐36) at time of enrollment and within 2.5 years of death were calculated for all groups. Statistical analysis utilizing ANCOVA (adjusting for age, sex, baseline MMSE and cognitive symptom duration) with pairwise comparisons, and Kaplan‐Meier curves were completed.ResultAge at onset of cognitive symptoms was not different between pathology groups. NPI‐Q scores at enrollment were highest in ADLB (7.33 ± 4.85), and higher (p<0.001) than DLB (5.10 ± 3.37), AD (4.54 ± 3.63) and controls (1.78 ± 1.70). At final evaluation, NPI‐Q scores were highest in DLB (10.04 ± 6.28), followed by ADLB (8.0 ± 4.), and ADD (7.61 ± 5.05) when compared to controls (2.78 ± 3.97) (all p<0.001). DLB and AD demonstrated significant increases in NPI‐Q severity during follow up (p < 0.001). AD had longer survival time (5.8 years) compared to ADLB (4.0 years) and DLB (3.9 years). Subjects with NPS had a shorter median survival time (3.4 years) compared to subjects without NPS (6.5 years; p = 0.002).ConclusionA higher NPS burden and shorter survival is seen in both DLB and ADLB, as compared with AD. This suggests that diffuse neocortical LB pathology is not the major driver of either NPS or survival.
Decline in cognitive trajectories in the neuropathological spectrum of Lewy Body disease
Choi, Alexander S., Belden, Christine M. , Mehta, Shyamal H. , Driver‐Dunckley, Erika, Shill, Holly A. , Beach, Thomas G. , Choudhury, Parichita , Zhang, Nan , Boeve, Bradley F. , Tremblay, Cécilia , Choi, Alexander, Driver‐Dunckley, Erika , Shprecher, David , Serrano, Geidy E. , Atri, Alireza

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S18 | Pages: No page available

10.1002/alz.079086 Get It

AbstractBackgroundPathological Lewy body disease (LBD) may commonly present clinically as Parkinson’s disease dementia (PDD), Dementia with Lewy bodies (DLB) or Alzheimer’s disease dementia (ADD). Neuropathological definitions also include a group in which ADD is present, but the postmortem Lewy pathology does not meet threshold density and distribution levels for the neuropathological diagnosis of DLB (ADLB). Little is known about the cognitive profiles of patients with ADLB and despite common underlying pathology, studies delineating neuropsychological profiles in LBD are fraught with inconsistencies. We characterized the longitudinal cognitive trajectories defined by neuropsychological profiles in cases along the pathological spectrum of LBD.MethodCases from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) with a cognitive diagnosis of dementia at death and who at minimum, had two neuropsychological evaluations were included. Final neuropathological diagnosis was determined as LBD (neocortical or limbic LB ± AD), ADLB, and AD pathology only. LBD cases were categorized by their cognitive clinical syndromes as PDD and DLB. Global cognition was evaluated using MMSE. Neuropsychological domains of Memory, Executive function, language, attention, and visuospatial were evaluated. Mixed linear methods were used to predict longitudinal change for a given baseline MMSE.Result287 participants and 1874 participant‐years of data were included in this study. LBD (n = 115), and ADLB (52) groups were predominantly male, while AD (n = 114) group was primarily female. Baseline MMSE was similar across all pathologic groups. Linear mixed modelling methods showed faster decrease in memory domain scores (decreasing 0.22 units/year – 0.42 units/year faster, p = 0.01) in ADLB group compared to other groups. Significantly faster decline was noted in LBD and ADLB group in clock drawing (p<0.001), fluency scores (declining 1.02 unit/year faster p<0.001) compared to AD group. There was no difference between PDD and DLB clinical subgroups.ConclusionIn autopsy confirmed cases, ADLB had an accelerated trajectory of decline in memory tasks, while AD, and LBD appeared to have similar trajectories. In contrast, all groups with Lewy bodies progressed faster and showed accelerated decline compared to AD in measures of frontal‐subcortical functions. These results may inform antemortem classification of patients and diagnostic accuracy in these groups.
Curriculum‐based CME Programming Results in Comprehensive Improvements in Knowledge, Competence, and Confidence in Diagnosing Early Forms of Alzheimer’s Disease Among a Global Audience of PCPs and Neurologists
Finnegan, Thomas , Stan, Adriana, McFarland, Frances, Chatterjee‐Shin, Piyali, Guedj, Philippe, Cohen, Sharon , Petersen, Ronald C.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S19 | Pages: No page available

10.1002/alz.077250 Get It

AbstractBackgroundEarly diagnosis of Alzheimer’s disease (AD) is crucial for ensuring patients have timely access to essential care. Given the symptoms of early AD are often subtle, it is important that both primary care physicians (PCPs) and neurologists are able to diagnose their patients. Several sources of evidence have indicated that most PCPs and neurologists lack knowledge, competence, and confidence regarding recognition of early forms of AD. To address the clinical practice gaps, a series of CME‐certified programs covering the symptoms, assessment, and diagnosis of early forms of AD were developed.MethodThe data presented here are based on outcomes from four online CME‐certified multimedia programs housed on a single destination page. Each CME‐certified program utilized expert physicians to educate learners on recognizing early forms of AD. Each CME program asked a series of pre‐post questions designed to assess immediate changes in knowledge, competence, or confidence. The questions were grouped into clinically relevant themes. The educational effect for all of the programs was determined by using a paired‐samples t‐test to identify significant differences between pre‐ and post‐assessment responses for each question. Data across all four programs were collected from February 2022 through December 2022. All four programs were promoted to an audience of US‐ and ex‐US physicians.ResultParticipation across the four programs ranged from 543 to 2,510 PCPs and 256 to 1,025 neurologists. PCPs and neurologists demonstrated significant (P<0.05) pre‐vs post education improvements on the following themes: biomarkers in AD, clinical trial outcomes, cognitive assessment scales, diagnosis of AD, diagnosis of mild cognitive impairment (MCI), and symptoms differentiating AD from MCI. Participation in the education also significantly (P<0.001) improved confidence in the identification of early forms of AD among PCPs and neurologists. No substantial differences in knowledge, competence, or confidence were seen for either clinician group based on geographic location of the learner.ConclusionThe results indicated that clinicians who participated in CME‐certified curriculum‐based education in multiple formats were better prepared to recognize early forms of AD. Future education should continue to discuss the use of clinical strategies to recognize early forms of AD.
Structural variants in Lewy body dementia and frontotemporal dementia spectrum
Ding, Jinhui , Rasheed, Memoona, Walton, Ronald L., Brand, Harrison , Zhao, Xuefang , Dewan, Ramita , Solaiman, Sultana , Dawson, Ted M. , Albert, Marilyn S. , Pletnikova, Olga, Troncoso, Juan C. , Masellis, Mario, Keith, Julia , Resnick, Susan M. , Ryten, Mina , Hardy, John , Mazzini, Letizia , Moglia, Cristina, Beach, Thomas G. , Graff‐Radford, Neill R. , Jager, Philip L. De , Hardy, John , Kaivola, Karri , Chia, Ruth , Fujita, Masashi , Menon, Vilas , Collins, Ryan L. , Billingsley, Kimberley J. , Talkowski, Michael E. , Ray, Anindita , Jerez, Pilar Álvarez , Malik, Laksh , Rosenthal, Liana S. , Pletniková, Olga , Black, Sandra E. , Ferrucci, Luigi , Tanaka, Toshiko , Topol, Eric J. , Torkamani, Ali , Tienari, Pentti J. , Foroud, Tatiana , Ghetti, Bernardino , Landers, John E. , Morris, Huw R. , D’Alfonso, Sandra , Moglia, Cristina , Calvo, Andrea , Serrano, Geidy E. , Ferman, Tanis J. , Boeve, Bradley F. , Wszołek, Zbigniew K. , Dickson, Dennis W. , Chiò, Adriano , Bennett, David A. , Ross, Owen A. , Dalgard, Clifton L. , Gibbs, J. Raphael , Traynor, Bryan J. , Scholz, Sonja W.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S12 | Pages: No page available

10.1002/alz.078497 Get It

AbstractBackgroundStructural variants range from simple loss or gain of genetic material to complex events that restructure entire chromosomes. This heterogeneity coupled with variant size greater than sequencing read‐length makes structural variant mapping from short‐read sequencing data difficult and error‐prone. Consequently, the role of structural variants is poorly explored in many phenotypes, including dementia.MethodWe used the GATK‐SV pipeline that combines four external structural variant mapping algorithms with machine‐learning to build high‐quality consensus structural variant calls. We applied GATK‐SV to short‐read whole‐genome sequencing data of 2,601 frontotemporal dementia‐amyotrophic lateral sclerosis spectrum (FTD/ALS) patients, 2,612 Lewy body dementia (LBD) patients, and 4,132 neurologically unaffected participants.ResultAfter stringent quality‐control, we performed genome‐wide association studies on 2,307 ALS/FTD patients versus 3,677 controls with 4,699 common structural variants and 2,355 LBD patients versus 3,700 controls with 4,889 common structural variants. In the FTD/ALS cohort, we identified well‐known risk variants at the C9orf72 (p‐value = 4.99×10‐18, OR = 14.47, 95% CI = 7.90–26.49) and MAPT loci (p‐value = 3.48×10‐6, OR = 0.77, 95% CI = 0.68–0.86) corroborating the ability of our pipeline to identify disease‐associated structural variants. Moreover, we discovered, replicated, and validated TPCN1 as a novel risk locus for LBD (p‐value = 9.18×10‐6, OR = 1.43, 95% CI = 1.22–1.67). Further, we identified rare exonic variants with known pathogenic or likely pathogenic effects, such as an SNCA gene duplication in LBD and a deletion of exons 1 and 2 in CHCHD10 in FTD/ALS. We additionally observed structural variants in regulatory regions, e.g. a deletion of a key PSEN2 enhancer, which resulted in an approximate 0.70 fold‐change in PSEN2 expression in LBD. Finally, we built an interactive web app where structural variants can be visualized and explored (https://ndru-ndrs-lng-nih.shinyapps.io/non_ad_dementias_sv_app/).ConclusionCommon and rare structural variants play a role in LBD and FTD/ALS. Our structural variant resource is publicly available and can be used to further explore the role of structural variants in LBD and FTD/ALS.
APOE4 impairs microglia‐astrocyte response in Alzheimer’s disease by inducing TGFβ‐mediated checkpoints
Yin, Zhuoran , Zhang, Xiaoming , Schroeder, Caitlin M., Silveira, Sebastian , Gauthier, Christian , Mallah, Dania, Durao, Ana, Herron, Shawn, Shorey, H. H., Cheng, Yiran , Barry, Jen‐Li, Wakelin, Sam, Rhee, Jared, Yung, Anthony , Aronchik, Michael, Jain, Nimansha , Bao, Xin , Brouwer, Nieske, Deik, Amy , Baufeld, Caroline, Tanzi, Rudolph E. , Arnold, Thomas D. , Butovsky, Oleg , Rosenzweig, Neta , Kleemann, Kilian L. , Brandão, Wesley Nogueira , Margeta, Milica A. , Pitts, Kristen M. , Shorey, Hannah, Wang, Chao , Gerrits, Emma , Tenen, Daniel Geoffrey , Ikezu, Tsuneya , Santander, Nicolas G. , McKinsey, Gabriel L. , Sheppard, Dean , Krasemann, Susanne , Eggen, Bart J. L. , Clish, Clary B. , Madore, Charlotte , Holtzman, David M.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S12 | Pages: No page available

10.1002/alz.076510 Get It

AbstractBackgroundAPOE ε4 is the strongest genetic risk factor for late‐onset Alzheimer’s disease (AD). The contribution of microglial APOE4 to AD pathogenesis is unknown, although APOE has the most enriched gene expression in neurodegenerative microglia (MGnD).MethodGeneration of CX3CR1‐CREERT2 mice crossed to APOE‐KI(E3 and E4)fl/fl: APP/PS1 and APOE‐KI(E3 and E4)fl/fl: P301S mice. Microglia and astrocytes were isolated and sequenced using either bulk RNA‐seq (MGnD‐Paradigm) or single‐cell RNA‐seq. Crosstalk between cells was determined using the NichenetR database and validated using 1) recombinant Lgals3 intracranial injection into APP/PS1 mice and 2) adoptive transfer of microglia, from APOE3‐KI, APOE4‐KI, and APOE4‐cKO mice challenged with labeled apoptotic neurons, into WT mice and isolation of astrocytes. Validation in the brain of AD donors carrying the APOE e3/3 and e3/4 alleles.ResultHere we show, in mice and in humans, a negative role of microglial APOE4 in the induction of MGnD response to neurodegeneration. Deletion of microglial APOE4 restores MGnD phenotype, associated with neuroprotection in P301S tau transgenic mice, and decreases pathology in APP/PS1 mice. MGnD‐astrocyte crosstalk associated with b‐amyloid (Ab) plaque encapsulation and clearance is mediated via Lgals3 signaling following microglial APOE4 deletion. In the brain of AD donors carrying the APOE ε4 allele, we found a sex‐dependent reciprocal induction of AD risk factors associated with suppression of MGnD genes in females, including LGALS3, as compared to APOE ε3/3 carriers. Mechanistically, APOE4‐mediated induction of ITGB8‐TGFb signaling impairs MGnD response via upregulation of TGFb‐mediated microglial homeostatic checkpoints, including INPP5D. Microglial deletion of Inpp5d restores MGnD‐astrocyte crosstalk and facilitates plaque clearance in APP/PS1 mice. Genetic and pharmacological blocking of ITGB8‐TGFb signaling enhanced MGnD response associated with increased plaque clearance in AD mice.ConclusionWe identify the microglial APOE4‐ITGB8‐TGFb pathway as a negative regulator of microglia‐astrocyte response to AD pathology, and restoring MGnD phenotype via blocking ITGB8‐TGFb signaling may provide new molecular targets to modulate and restore functional microglia in AD.